文献速递肝肾功能剂量调整

成人急性髓系白血病中吉妥珠单抗奥唑米星群体药代动力学模型

Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

本研究整合7项I/II期研究数据,用非线性混合效应模型描述吉妥珠单抗奥唑米星在成人急性髓系白血病患者中的群体药代动力学。总hP67.6抗体在407例患者中采用二室模型拟合,非结合卡奇霉素在338例患者中拟合。轻中度肾功能或肝功能损害不影响总hP67.6抗体处置,模型模拟为3 mg/m2第1、4、7天给药方案提供药代动力学依据。

要点

  • 总hP67.6抗体在407例患者中可用二室模型描述,含线性和时间依赖性清除。
  • 非结合卡奇霉素在338例患者中拟合,其生成速率取决于hP67.6消除量。
  • 轻中度肾功能或肝功能损害患者总hP67.6抗体处置未见明显改变。

核心结论

  • 总hP67.6抗体在轻中度肾功能或肝功能损害患者中处置未见明显改变。
  • 模型模拟为3 mg/m2第1、4、7天给药方案提供药代动力学依据。

研究设计与样本

  • 整合7项既往成人急性髓系白血病I/II期研究的药代动力学数据。
  • 总hP67.6抗体在407例患者(5643个浓度)中采用二室模型拟合,剂量范围0.25至9 mg/m2。
  • 非结合卡奇霉素在338例患者(4281个浓度)中采用二室模型拟合。

主要发现

  • 总hP67.6抗体药代动力学采用含线性和时间依赖性清除的二室模型描述。
  • 非结合卡奇霉素药代动力学采用二室模型描述,生成速率取决于hP67.6消除量。
  • 性别、白蛋白、骨髓和外周原始细胞百分比等基线协变量无临床意义影响。

关键数值与推荐

  • 总hP67.6抗体剂量范围0.25至9 mg/m2。
  • 获批给药方案为3 mg/m2第1、4、7天。

临床怎么用

  • 轻中度肾功能或肝功能损害患者无需基于肝肾功能调整总hP67.6抗体暴露。
  • 3 mg/m2第1、4、7天方案有模型模拟药代动力学依据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Gemtuzumab ozogamicin is an antibody-drug conjugate composed of the anti-CD33 monoclonal antibody hP67.6 covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide, a potent cytotoxic antibiotic. The aim of this study was to characterize the population pharmacokinetics of gemtuzumab ozogamicin, represented by total hP67.6 antibody and unconjugated calicheamicin, in adult patients with acute myeloid leukemia to support drug dosing strategies and explore intrinsic and extrinsic factors that may influence exposure. Pharmacokinetic data from seven previous phase I and II studies in adult patients with relapsed, refractory, or de novo acute myeloid leukemia were integrated and analyzed using nonlinear mixed-effects modeling. METHODS: The pharmacokinetics of total hP67.6 antibody was described in 407 patients (5643 concentrations) who received gemtuzumab ozogamicin doses ranging from 0.25 to 9 mg/m2 using a two-compartment model with linear and time-dependent clearance components. The pharmacokinetics of unconjugated calicheamicin was characterized in 338 patients (4281 concentrations) using a two-compartment model with an input rate of formation dependent on the amount of hP67.6 eliminated. No statistically significant baseline covariates (sex, albumin, bone marrow, and peripheral blast percentage) demonstrated a clinically meaningful impact. RESULTS AND CONCLUSION: Total hP67.6 antibody disposition did not appear altered in patients with mild or moderate renal disease or hepatic impairment. Gemtuzumab ozogamicin was approved for the treatment of acute myeloid leukemia by the US Food and Drug Administration in September 2017. The model-based simulations described here provided a pharmacokinetic rationale for the approved dosing regimen of 3 mg/m2 on days 1, 4, and 7, and served as the basis for all exposure-response modeling included in the recent Biologics License Application submission. Clinical trials identifiers: 0903A1-101-US; 0903A1-103-JA; 0903B1-201-US/CA (NCT00003131); 0903B1-202-EU; 0903B1-203-US/EU (NCT00003673); 0903B1-205-US/EU/AU (NCT00037596); and 0903B1-206-US/EU/AU (NCT00037583).

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Hibma J, Knight B. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia. Clin Pharmacokinet. 2019. PMID: 30062662. doi:10.1007/s40262-018-0699-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。